Nexalin Technology, Inc. NXL 深 滬
已收盤 02-06 16:00:00 美东时间
0.5149
-0.105
-16.95%
華盛通- 最 高0.68
- 今 開0.60
- 成交量 118.87万股
- 最 低 0.50
- 昨 收 0.62
- 總市值 960.39万
- 52周最高 3.5399
- 市盈率 靜 --
- 換手率 6.37%
- 52周最低 0.50
- 委 比 41.48%
- 總股本 1865.19万
- 歷史最高 4.4899
- 量 比 0.92
- 振 幅 29.03%
- 歷史最低 0.2528
- 每 手 1
- 風險率 0.67%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Nexalin Technology Validates DIFS™ Neurostimulation with New Clinical Research Across Multiple Brain Disorders
Nexalin Technology Validates DIFS™ Neurostimulation with New Clinical Research Across Multiple Brain Disorders Nexalin Technology Inc. has highlighted new peer-reviewed clinical research validating its proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology across multiple neurologica
02-02 21:45
Nexalin Notified Recieves NASDAQ Minimum Bid Price Deficiency Letter, Has Until July 20, 2026 To Comply
Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has received a notification
01-24 06:22
Nexalin Technology Receives Nasdaq Listing Status Notification
<p>Nexalin Technology, Inc. (Nasdaq: NXL) has received a notification from NASDAQ indicating non-compliance with the minimum bid price requirement of US$1.00 per share under Listing Rule 5550(a)(2). The company has 180 days until July 20, 2026, to regain compliance by achieving a closing bid price of at least US$1.00 for 10 consecutive trading days. Failure to meet this requirement may result in delisting. Nexalin is monitoring its bid price and ...
01-23 22:15
Nexalin Technology Announces Publication Of New Peer-Reviewed Clinical Study In Molecular Psychiatry Demonstrating DIFS Technology Improves Attention And Normalizes Brain Activity In Patients With ADHD
Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the publication of a new peer-reviewed
01-14 22:04
Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD
Nexalin Technology announced the publication of a study in *Molecular Psychiatry* showcasing their DIFS™ neurostimulation technology's effectiveness in improving ADHD symptoms and brain function in adults. The randomized, double-blind trial of 56 adults showed a 10.1-point improvement in ADHD symptoms compared to a 5.5-point improvement in the sham group. Advanced neuroimaging revealed reduced excessive gamma activity and improved brain network c...
01-14 14:00
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4
Nexalin Technology, Inc. (Nasdaq: NXL) invites investors to a webinar on December 4, 2025, at 4:15 p.m. ET, hosted by RedChip Companies. CEO Mark White will discuss Nexalin's innovative Deep Intracranial Frequency Stimulation (DIFS™) technology for mental healthcare, clinical evidence, and updates on the Gen-3 HALO™ Clarity headset and Virtual Clinic model. Nexalin, with international regulatory approvals and U.S. expansion underway, targets the ...
2025-12-02 13:00
Nexalin Technology Signs Exclusive Distribution Agreement With Carmi Masha Technologies To Advertise, Sell Nexalin's Gen-2 Console In Israel
Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has entered into an exclusive distribution
2025-11-13 22:21
Nexalin Technology Receives Approval To Sell Its Gen-2 Console Device In Israel
Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that its Gen-2 Console ("SYNC"), 15 milliamp (mA)
2025-10-30 20:31
Nuix Withdraws CEO Performance Rights Resolutions Amid Leadership Change
Nuix Ltd. ( ($AU:NXL) ) just unveiled an announcement. Nuix Limited has announc...
2025-10-27 14:27
